Numinus

Innovative Research into Psychedelic Therapies

This Numinus profile is part of a paid investor education campaign.*

Overview

Numinus is at the forefront of the transformative change in treating the growing prevalence of mental health issues and addressing people’s desire for greater wellness. The company offers a unique, integrated therapeutic model to create lifelong relationships with people wanting lasting physical, mental and emotional health — with a focus on treating mental health and substance abuse. 

In addition to services including counselling, neurofeedback, physiotherapy and other therapies, Numinus aims to guide people identified as suitable candidates in the use of psychedelics and supportive therapies to help them heal, connect and grow. Numinus will conduct these therapies in a safe, controlled therapeutic environment in partnership with various health and research organizations, and the use of psychedelics will only proceed in accordance with regulatory approval.

Numinus’ unique growth platform includes a testing and research facility that can leverage the emerging market of psychedelic therapies to treat mental illness, addictions and PTSD, as well as an established and fully integrated treatment and healing centre model that the company plans to scale nationally.

numinus clinic

Looking to capitalize on its dealer’s licence and first-mover advantage in the space, Numinus intends to test, process, buy, sell and conduct clinical trials on various psychedelics and cannabis. The dealer’s licence is essential for the company to advance its research into psychedelic-based treatments as are Numinus’ research partners.

Numinus was founded by Payton Nyquvest and Stacey Wallin, who both have a passion for developing holistic therapies that deal with the root causes of mental illness, addictions and trauma. The two founders have a wealth of experience in bringing innovative companies to the capital markets. Nyquvest, for example, has raised over C$100 million for public and private companies alike and has facilitated numerous IPOs, including Numinus’ pending RTO with Salvation Botanicals and Rojo Resources Ltd. Joining the team as Chief Operating Officer is Michael Tan, who was the first director for the British Columbia Liquor Distribution Branch’s (BCLDB) cannabis division. He also has a track record of driving profitable revenue growth.

Numinus’ Company Highlights

  • RTO with Salvation Botanicals and Rojo Resources Ltd. is expected to be completed in Q1 2020.
  • Numinus intends to develop psychedelic therapies to treat mental illness, addictions and PTSD.
  • The company received its dealer’s licence in July 2019, which allows Numinus to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT and mescaline. Joining the team as Chief Operating Officer is Michael Tan.
  • 7,000-square-foot laboratory can perform 100,000 cannabis tests per year and is set to be a progressive player in the hemp-derived CBD and cannabis extraction markets upon issuing of its standard processing licence by Health Canada, expected in Q1 2020.
  • Sustainable cannabis revenue through the testing and productions operations is expected to fund Numinus’ growth plans.
  • The cannabis portion of the business has the potential to bring in C$25 million, dependent on timing of receiving Health Canada processing licence and production facility operating at capacity.
  • The company plans to build a network of transformative healing centres across North America, staffed with professional therapists and integrative health professionals.
  • Numinus plans to add two to four new centres across Canada in 2020.
  • Combined revenue for the healing centre and testing/research facility is expected to hit C$5 million in 2020.
  • Research partnerships in place with MAPS and Together We Can and Memorandum of Understanding signed with the BC Centre on Substance Use (BCCSU).

Regulators Turning to Psychedelic Therapies to Treat Mental Illness and Addiction

In 2017, psychedelic therapies were designated as a breakthrough therapy by the FDA due to the growing need for solutions for mental health-related issues across the globe. According to the World Health Organization, mental disorders affect one in four people at some point in their lives, and approximately 450 million people currently suffer from mental health issues, making it a leading cause of ill-health and disability worldwide.

If left untreated, mental health disorders can cost Canadians C$51 billion per year in health care costs, lost productivity and reductions in health-related quality of life, according to the Centre for Addiction and Mental Health (CAMH). Despite the patient costs associated with mental illness, conventional health care frameworks have made a limited impact, creating a need for innovative treatments to be developed.

Safe and controlled psychedelic-based treatments offer a potential solution and have been slowly moving into mainstream health care channels. Many research organizations, such as BCCSU, have been testing the efficacy of treating mental health disorders with various psychedelics. Johns Hopkins University has also entered the fray by opening a new US$17 million centre dedicated to psychedelic research.

Numinus’ Patient-First Business Model

Numinus is an in-market and fully integrated company that intends to serve the psychedelic therapy space. The company’s unique platform includes a facility that it plans to use to target the emerging market for psychedelic therapies that can treat mental illness, addiction and PTSD. Numinus also has an established healing centre that the company plans to scale nationally.

In addition to exploring the therapeutic uses of psychedelics, Numinus plans to create a sustainable revenue stream through its testing and productions operations by developing cannabis products, once it receives Health Canada approval (expected in Q1 2020). The company estimates that it can generate approximately C$5 million in revenue in 2020 through its lab facility and healing centre.

Testing and Research

Numinus owns a 7,000-square-foot laboratory, which uses proprietary technology in addition to chromatography, spectroscopy and mass spectroscopy techniques. The facility is staffed by internationally-acclaimed PhDs with backgrounds in peer-reviewed research, pharmaceutical manufacturing and advanced analytical technologies.

The company received its dealer’s licence under the Controlled Substances Act in July 2019, providing Numinus with a first-mover advantage in the psychedelics space. The licence allows the company to test, process, buy and sell various psychedelics. It also meets FDA Stage 3 requirements to conduct clinical trials.

Numinus has established partnerships with leading Canadian universities and institutions to advance its research into psychedelic-based treatments. One such collaboration is with a leading Canadian university with a patented process for producing psychedelic products for a growing number of clinical research trials.

The Numinus Healing Centre

Numinus owns an operational facility that employs professional therapists and health practitioners to help people heal, connect and grow. Numinus also aims to guide people identified as suitable candidates in the use of psychedelics and supportive therapies. Numinus will conduct these therapies in a safe, controlled therapeutic environment in partnership with various health and research organizations, and the use of psychedelics will only proceed in accordance with regulatory approval.

The centre offers a full suite of therapeutic services including naturopathic medicine, craniosacral therapy and registered massage therapy. The company’s first healing in Vancouver includes six treatment rooms, event and studio space and a 15-person therapeutic team that includes doctors of medicine and naturopathy, and registered nurses.

Numinus plans to expand its healing centre footprint and brand by acquiring two to four more centres in Canada that are aligned with the company’s model. The company also plans to conduct research and clinical trials with BCCSU and Together We Can, to advance therapeutic, evidence-based patient studies in psychedelic therapies.

Cannabis

Numinus will be backstopped by stable cannabis revenue. Sustainable cannabis revenue driven by our testing and productions operations laboratory provides us a foundation for growth – differentiating them from others in the psychedelics space.

Numinus has the capacity to take on THC and CBD product, and is set to be a progressive player in the hemp-derived CBD and cannabis extraction markets upon issuing of its standard processing licence by Health Canada, expected in Q1 2020. Their facility has an extraction capacity of three billion milligrams per year, can fill 300,000 sellable capsules per day and perform 100,000 cannabis tests per year.

The cannabis portion of the business has the potential to bring in C$25 million, dependent on timing of receiving Health Canada processing licence and production facility operating at capacity.

Numinus’ Management Team

Payton Nyquvest — Founder, Chairman and CEO

Payton Nyquvest founded Numinus out of a lifelong interest in health, wellness and personal development, triggered by mental health and chronic autoimmune problems in his earlier years. Transformational therapies helped to save his life, and he is driven to provide public access to these therapies.

He is a former Director, VP and Head of Sales at Mackie Research Capital, with 15 years of experience focusing on early-stage companies in multiple industries including technology, healthcare, biotech, cleantech and cannabis. He has raised over $100 million for more than 100 public and private companies and facilitated numerous IPOs.

Stacey Wallin — Founder and Chief Strategy Officer

Stacey Wallin founded Numinus with a passion for holistic wellness after a series of near-death experiences in 2015 related to illness and misdiagnosis, which inspired her to begin studying and advocating awareness for mind-body health. She previously founded and was CEO of LifeBooster, a tech startup now helping Fortune 100 clients detect and proactively respond to workplace injury risks. She most recently was the Director of Venture Programs at the BC Tech Association with a mandate of solving the largest ecosystem and policy-related challenges facing growth and scale-stage technology companies.

Michael Tan — Chief Operating Officer

Michael Tan is the former and first executive director of the BCLDB’s Cannabis Division, where he successfully launched cannabis operations in British Columbia. Michael has 20 years of strategic planning and execution with national and multinational corporations. He is a high-impact product development, marketing and operations executive with a track record of driving profitable revenue growth.

Kraig Docherty — Chief HR Officer

Kraig Docherty has over 20 years of experience growing and scaling tech and creative companies such as EA, Activision Blizzard, Indochino, Invoke and Eventbase.

John Fong — Chief Financial Officer

John Fong is a professional accountant with over two decades of experience in financial and operational management. He provides stability and growth solutions to public natural resource companies and technology start-ups.


*Disclaimer: This profile is sponsored by Numinus. This profile provides information which was sourced by the Investing News Network (INN) and approved by Numinus, in order to help investors learn more about the company. Numinus is a client of INN. The company’s campaign fees pay for INN to create and update this profile.

INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.

The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Numinus and seek advice from a qualified investment advisor.